Key Highlights

  • Boston Scientific (NYSE:BSX) fell 5.8% to 6.3% on October 28, 2026 after its fourth-quarter outlook, with an early low of 11% down, partly recovered. One account says fourth-quarter sales will be 1% to 3% below a year earlier, which is not confirmed.
  • Teladoc (NYSE:TDOC) rose 8% to 9% after hours on October 28, 2026, with quarterly revenue of USD 605.1 million. The guidance details and analyst consensus behind the beat-and-raise reading were not retrieved, so its size is unknown.
  • Align Technology (NASDAQ:ALGN) fell 5% after hours on October 28, 2026, which a published account links to weak guidance and cost inflation. The guidance figures and the earnings results were not retrieved, so the cause is not confirmed.
  • SELLAS Life Sciences (NASDAQ:SLS) fell 15% to 16% on October 28, 2026 after saying its REGAL trial reached the event count for final analysis, with results expected this quarter. The release reported no efficacy data.

Boston Scientific (NYSE:BSX): Outlook disappoints

Boston Scientific (NYSE:BSX) shares fell 5.8% to 6.3% on October 28, 2026, after the company's fourth-quarter outlook, with an early low of 11% down, according to published market data. The direction of the guide is verified as weaker than hoped. One account says fourth-quarter sales will be 1% to 3% below a year earlier, but that wording is unusual for a company that has generally grown sales, and the material reviewed advises confirming it. It may be a mangled growth rate or a comparison to a prior forecast, so readers should treat the 1% to 3% figure as unconfirmed pending the company release. Because the reviewed material did not include the third-quarter results themselves, this article cannot say whether the quarter beat estimates. Medical device companies are valued on steady procedure growth, so a fourth-quarter outlook that disappoints can reset expectations for the next year. For Boston Scientific (NYSE:BSX), a maker of devices used in cardiology and other procedures, guidance matters because analysts build models from quarterly targets and annual ranges. If management trims the near-term path, the market may cut its estimate of the full-year result and apply a lower multiple. The early drop of 11% followed by a smaller close suggests buyers stepped in after the first reaction, a pattern that can occur when an initial headline reading proves harsher than the detail.

Teladoc (NYSE:TDOC): Beat-and-raise reading

Teladoc (NYSE:TDOC) rose 8% to 9% after hours on October 28, 2026, and its quarterly revenue was USD 605.1 million. The same trading session saw eBay rise 5% on earnings per share of USD 1.51 and Glaukos rise 13%. Bausch Health and GFL Environmental also jumped, though the gains were not sized in the account used here. The moves are verified in published market data, but the full results and any guidance changes behind them were not retrieved. The range of 8% to 9% for Teladoc reflects different quotes taken at different minutes, which is common when after-hours trading is thin and prices move with each new order. A beat-and-raise combines two events: reported results above the analyst consensus and a higher outlook for coming quarters. Investors often pay more for the second part, because raised guidance lifts estimates for several periods rather than just one. The companies here sit in different industries, from digital health and online marketplaces to eye-care devices, so the common thread is results rather than sector news. For Teladoc (NYSE:TDOC), a digital health services provider, revenue of USD 605.1 million matters mainly against what analysts expected, and that consensus figure was not retrieved. The reaction therefore points to a favorable surprise without proving its size, and each company release should be read for its own numbers.

Align Technology (NASDAQ:ALGN): Described weak guidance

Align Technology (NASDAQ:ALGN) fell 5% after hours on October 28, 2026, and Amrize fell 7%. The account behind the move attributes both to weak guidance and cost inflation, and contrasts them with a 6.67% gain for Honeywell Aerospace. A second account gives Honeywell Aerospace a decline of 3.5% instead, so the direction of that move is open and no tag or conclusion is drawn for it here. The Align and Amrize moves are verified, but the guidance figures, the earnings results and the cost details were not retrieved. This article therefore reports the reaction and the stated cause without adding numbers that could not be matched. Guidance is management's forecast for coming quarters, and analysts reset estimates to match it. When the forecast is below consensus, the share price usually falls even if the quarter just reported was fine. Cost inflation adds a second pressure: if materials, labor or freight cost more, margins narrow unless prices rise. Align Technology (NASDAQ:ALGN) sells clear aligners and scanners, and a building-materials business such as Amrize buys heavy inputs, so both can feel cost pressure in different ways.

SELLAS Life Sciences (NASDAQ:SLS): Trial readout approaching

SELLAS Life Sciences (NASDAQ:SLS) said in a company release that the REGAL trial had reached the number of events required for final analysis, and that results are expected this quarter. Published market data show the stock fell 15% to 16% on October 28, 2026. The release itself did not report efficacy, so the drop cannot be tied to any data. It is also not stated in the material reviewed whether the company gave a more precise date than this quarter. Investors therefore face a fixed deadline without knowing the outcome, which is why the shares can move sharply on the announcement alone, in either direction, before any result is public. In an event-driven trial, the statistical analysis is triggered by a prespecified number of events, such as deaths, instead of by a calendar date. Once the count is reached, the dataset is locked and independent statisticians compare the treatment and control arms. The step also removes the long wait that normally supports a share price, because the open question becomes a near-term binary test. One reading, offered as interpretation and not as a finding, is that some holders sold into the news to avoid the readout risk, though no confirmed reason for the decline was found.

Where Things Stand

The answer is that healthcare split three ways on October 28. Boston Scientific (NYSE:BSX) fell on a disappointing outlook. Teladoc (NYSE:TDOC) rose on a beat-and-raise reaction. Align Technology (NASDAQ:ALGN) fell on described weak guidance. SELLAS Life Sciences (NASDAQ:SLS) fell as a pivotal trial neared a binary readout. Stryker (NYSE:SYK) reports after the close on October 29, 2026, which may show whether device pressure is wider. This is not investment advice.